
Amgen to join exclusive Dow Jones club

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Interlink shares rise despite earnings drop

Interlink Electronics shares popped 36 percent to a new 52-week high ahead of an earnings report on Aug. 17 that showed a 15 percent dip in revenue but net income that stayed barely in the black. The results come as the sensor manufacturer is preparing to move into a new headquarters in Irvine and make Read More →

Pandemic has silver lining for Trade Desk

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Inogen revenue falls, but Q2 earnings beat analyst estimates

The COVID-19 pandemic continued to cut into Inogen’s revenue, as new physician referrals and patient mobility declined during a quarter usually marked by increased patient travel and demand. Revenue fell nearly 30 percent in the second quarter to $71.7 million, missing average analyst estimates, and net income of $2.7 million was down from $9.9 million Read More →
Amgen teams up with competitors in COVID treatment trial

Amgen has joined two of its competitors in launching a trial for drugs to treat patients with COVID-19. Together with Chicago-based AbbVie and Japanese drugmaker Takeda Pharmaceutical, the Thousand Oaks biotech giant said Aug. 3 it had enrolled the first patients into a clinical trial for the anti-inflammatory drugs Otezla, cenicriviroc and Firazyr. Otezla is Read More →